Recorded device evidence

EL27-Compact; Sterile EHL-Probes (K230488): indications, design and recorded evidence

The acquired K230488 file contains product-specific indications and users, design and operating principle, recorded comparison and differences, non-clinical evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-07. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 4 selected decisions under primary code FFK. 4 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K230488 ↗ · this pageEL27-Compact; Sterile EHL-Probes2023-02-23 → 2023-08-31189Traditional
K243032 ↗EHL Probe (SCDG-AS); EHL Probe (SCDG-BS); EHL Probe (SCDG-CS)2024-09-27 → 2025-03-21175Traditional
K242888 ↗Electrohydraulic Lithotriptor (TCS-B3-II)2024-09-23 → 2025-03-21179Traditional
K202813 ↗URO-TOUCH 9 French Probe2020-09-24 → 2021-06-14263Traditional
K191124 ↗Swiss LithoClast Trilogy2019-04-29 → 2019-05-2930Special

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K230488 · PDF page 3 ↗ Source 2

Read this statement in the original PDF; no complete statement fits the short excerpt.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K230488 · PDF page 5 ↗ Source 3

The EL27-Compact is a device, designed to be used with Walz Elektronik GmbH disposable EHL-
Probes for the fragmentation of concrements in the gastroenterology and urology.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Recorded comparison and differences

K230488 · PDF page 6 ↗ Source 4

Generator

      -                                                              Both devices, the predicate and the subject of this 510(k) submission, are used in the
            field of urology and gastroenterology for fragmentation of concrements.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: The summary’s comparison is a manufacturer statement about that submission. Investigate the actual design differences and cited records before considering any comparator or predicate.

Non-clinical evidence actually described

K230488 · PDF page 7 ↗ Source 5

These comprehensive validation bench tests support equivalence to the predicate device. Testing
confirmed that comparable effects could be achieved for applicable modes of operation.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK230488 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryEL27-Compact; Sterile EHL-Probes [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantWalz Elektronik GmbH [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeFFK [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2023-08-31 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2023-02-23 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Recorded comparison and differences — what differs in our product?

    The summary’s comparison is a manufacturer statement about that submission. Investigate the actual design differences and cited records before considering any comparator or predicate.

    Useful evidence: Feature-by-feature differences and the underlying cited documents; no automated predicate selection.

  4. Non-clinical evidence actually described — what differs in our product?

    Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

    Useful evidence: Existing protocols/results and design-specific evidence gaps, with standard editions and scope reviewed separately.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[176264] · record 375df9efee27a56262a0ae917623b540dbf050cf89ad2750970f1ae9dd60cf91
  • [6] Complete results array / fda-decision-context:K230488 · record whole dataset partition

FDA 510(k) summary — K230488 ↗

Fri, 01 Sep 2023 17:25:34 GMT · retrieved 2026-10-07

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot 5533c24831b401cb14fa7e2c53048108e94ba1138043ec99b96b792adf5678ab

  • [2] PDF page 3 · record b2e3cd8a046d5ba24131d7b9677183aa1a78eb2926061c95380c8b51df3a2b83
  • [3] PDF page 5 · record 949d5e9af5ec5e888df2b68627de6208c65c69f006918034b0b7e55e3c42a11a
  • [4] PDF page 6 · record f003bd7e31cd404a5304bc89609b57a68919030ddc41015ed83686af6d89ddcd
  • [5] PDF page 7 · record ab5c0bfed5effda5f6ef5b241ddde105125b10d7580a098e9c0618e74a7e3436

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services